1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Parnax Lab Limited

Parnax Lab Limited

103.50
INR
-0.55
(-0.53%)
7.80EPS
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
80.63
120.81
83.7
111.48
124.04
127.9
112.07
105.89
191.53
151.42
164.3
163.45
216.4
219.5
Basic EPS, GAAP
2.93
5.01
2.95
4.33
1.24
3.88
-3.43
-0.43
9.68
7.79
8.37
10.03
10.25
7.79
Free Cash Flow per Basic Share
-0.17
-0.3
4.1
6.13
9
-3.06
-5.22
2.08
-10.9
8.7
1.52
19.63
-23.91
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
24.57
29.56
32.5
36.88
38.23
42.01
38.56
38.26
49.1
54.11
62.32
72.35
82.83
- -
Tangible Book Value per Share
24.54
29.54
32.48
36.7
37.97
41.69
38.32
38.1
49
53.91
61.63
71.65
82.24
- -
Basic Weighted Avg Shares
9
9
9
9
9
9
9
9
9
11
11
11
11
11
Sales/Revenue/Turnover
686
1,027
712
948
1,055
1,088
953
901
1,630
1,676
1,887
1,877
2,485
2,520
Operating Margin (%)
10.06
9.63
10.48
9.96
7.99
6.81
2.31
5.54
10.56
9.99
8.84
10.54
9.46
6.27
Depreciation Expense
21
30
29
38
37
38
45
52
59
65
70
74
80
83
Net Income, GAAP
25
43
25
37
11
33
-29
-4
82
86
96
115
118
89
Effective Tax Rate (%)
26.83
21.76
27.97
21.64
65.06
28.45
- -
- -
32.66
29.7
20.12
26.38
25.83
25.72
Profit Margin (%)
3.64
4.14
3.52
3.89
1
3.03
-3.06
-0.4
5.06
5.14
5.09
6.14
4.74
3.55
Working Capital
50
69
-4
-56
-7
6
-68
-151
-62
-20
-64
-60
-28
- -
LT Debt
203
256
202
171
167
216
199
171
206
153
299
262
294
- -
Total Equity
209
252
277
314
326
358
329
326
483
623
717
832
953
- -
Return on Invested Capital (%)
5.35
7.23
3.75
5.21
3.42
7.14
- -
- -
11.48
10.2
10.23
9.68
8.99
- -
Return on Capital (%)
10.3
12.9
8.21
10.69
3.57
8
- -
- -
11.21
10.28
10.25
10.07
9.59
- -
Return on Common Equity (%)
12.69
18.5
9.5
12.49
3.3
9.67
-8.51
-1.11
20.42
15.62
14.37
14.89
13.21
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
534
- -
LT Borrowings
- -
217
- -
LT Finance Leases
- -
77
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
- -
- -
- -

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
930
- -
Cash, Cash Equivalents & STI
- -
23
- -
Accounts Receivable, Net
- -
378
- -
Inventories
- -
362
- -
Total Current Liabilities
- -
958
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
534
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.08%
24.54%
14.49%
Free Cash Flow
-4.57%
12.3%
-221.75%
Net Income, GAAP
-241.38%
-465.29%
2.24%
Sales/Revenue/Turnover
15.8%
25.66%
32.39%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
501
484
402
490
1,877
2026
534
626
629
696
2,485
2027
568
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.47
2.97
1.06
2.55
10.03
2026
2.85
3.15
2.37
1.9
10.25
2027
0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Mihir Prakash Shah
Full Time Employees
12
Sector
Health technology
Industry
Pharmaceuticals: major
Address
1109/1110 ‘A’ Wing Mumbai MA India 400098
IPO Date
Sep 15, 2009
Website
naxparlab.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Parnax Lab Limited manufactures and exports pharmaceutical formulations, cosmetics, herbal and ayurvedic products, and nutraceuticals from its WHO-approved and EHS-compliant facilities in India, with operations extending internationally; the company, founded in 1982 and headquartered in Mumbai, forms part of the Naxpar Group and specializes in contract manufacturing of liquid orals, capsules, ointments, external powders, tablets, suspensions, and highly viscous products. Core offerings encompass oral formulations including cough expectorants such as NAXODEX Cough Syrup, Bronax Expectorant, and Pneumokof Expectorant; antacids like Gasknot Gel; anti-histamines such as Alerzine Syrup and Daslin NF Syrup; multi-vitamins and enzyme preparations; pediatric formulations like Febrinax Plus DS, Naxpar Gripe Water, and Brupaed Suspension; special geriatric formulations; cosmetics including Anti Druf Lotion; and nutraceuticals alongside other brands like Nax-P Syrup, Naxidex Syrup, Periact Syrup, Nerodex Cough Syrup, Kure Mouth Ulcer Gel, and Piromine Tablet. In recent developments, Parnax Lab maintains ongoing private label manufacturing for customers in India and abroad, sustains upgrades to its Silvassa facility for enhanced production capacity, and reports active share price momentum amid potential new product launches targeted for revenue growth in 2025.